The JAK3 Knockout DLD-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the DLD-1 human colorectal adenocarcinoma cell line, engineered to disrupt the JAK3 gene. This product provides a heterogeneous pool of cells with targeted loss-of-function of Janus kinase 3, enabling researchers to study the functional consequences of JAK3 ablation in an epithelial cancer background without selecting for individual clonal variants. The polyclonal format captures the genetic diversity generated by CRISPR-mediated gene disruption, offering a more representative model of population-level responses than monoclonal isolates.
The DLD-1 cell line is a well-characterized human colorectal adenocarcinoma model derived from a male patient with colorectal cancer. These cells exhibit epithelial morphology and retain key mutations commonly found in colorectal tumors, including activating mutations in the RAS/RAF pathway and mismatch repair deficiency, making them particularly relevant for studying colorectal cancer biology. DLD-1 cells are widely used in cancer research for investigating proliferation, invasion, drug resistance, and signaling pathways.
JAK3 is a non-receptor tyrosine kinase that specifically associates with the common gamma chain (??c) of interleukin receptors. Upon cytokine binding??by IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21??JAK3 is activated and cooperates with JAK1 to phosphorylate receptor chains, recruiting STAT transcription factors. Activated JAK3 primarily phosphorylates STAT5, and also targets STAT3 and STAT6, promoting their dimerization and nuclear translocation to drive expression of BCL2, MYC, and SOCS1. This JAK-STAT signaling axis regulates cell proliferation, survival, and differentiation, predominantly in immune cells, but aberrant JAK3 activity is increasingly recognized in solid tumors.
In the DLD-1 colorectal adenocarcinoma context, JAK3 knockout provides a valuable tool to dissect the contribution of JAK-STAT signaling to tumor cell biology. While JAK3 is traditionally viewed as a lymphoid-specific kinase, its expression has been reported in some non-hematopoietic cancers, and inflammatory cytokine signaling in the tumor microenvironment can influence epithelial cancer cell behavior. This knockout model allows researchers to investigate whether JAK3 loss affects DLD-1 proliferation, apoptosis, or response to cytokine stimuli, and to assess the role of JAK3 in pathways relevant to inflammatory bowel disease-associated colorectal cancer.
Typical applications include cytokine stimulation assays to evaluate phospho-STAT5 levels by flow cytometry or western blotting, cell proliferation and apoptosis assays under varying culture conditions, and drug screening for JAK inhibitors. RT-qPCR and immunoblotting can confirm JAK3 ablation and downstream target regulation. This polyclonal knockout cell population is also suitable for studying cancer immunology and validating therapeutic targets in the context of colorectal adenocarcinoma. For additional information and ordering, please contact Ascent Research.
